
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CytoDyn Inc is a biotechnology business with stocks listed in the US. CytoDyn shares (CYDY) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was US$4.28 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$0.911 - US$10.01 |
---|---|
50-day moving average | US$4.2794 |
200-day moving average | US$3.8318 |
Target price | US$4 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.188 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $4.28
1 week (2021-04-15) | 40.33% |
---|---|
1 month (2021-03-23) | 86.09% |
3 months (2021-01-22) | -14.49% |
6 months (2020-10-22) | 59.70% |
1 year (2020-04-22) | 63.58% |
---|---|
2 years (2019-04-22) | 866.14% |
3 years (2018-04-20) | 739.22% |
5 years (2016-04-22) | 241.04% |
Gross profit TTM | US$0 |
---|---|
Return on assets TTM | -77.37% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | 0.005 |
Market capitalisation | US$1.4 billion |
TTM: trailing 12 months
We're not expecting CytoDyn to pay a dividend over the next 12 months.
Over the last 12 months, CytoDyn's shares have ranged in value from as little as US$0.911 up to US$10.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.4957. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
Steps to owning and managing Roblox shares.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.